Before delving into the details of the study, it is important to understand what Myeloproliferative Neoplasms (MPN) are. MPNs are rare types of blood cancers that arise from excessive production of red blood cells, platelets or white blood cells in the bone marrow.Â
Content guide
Understanding Myeloproliferative Neoplasms (MPNs)
The main subtypes of MPNs are Myelofibrosis (MF), Polycythemia Vera (PV) and Essential Thrombocythemia (ET). Each of these types of MPN presents its own unique challenges. Myelofibrosis is a particularly severe condition that results in the development of fibrous tissue in the bone marrow, like scars in the marrow, which impairs normal blood cell production. The severity of MPNs is classified as low, intermediate or high risk, according to the various scales of the International Prognostic Scoring System.
Dr. Warren Fiskus' Promising Research at ASH23
Focusing on the clinical study, Dr. Warren Fiskus, a well-known specialist in the field of hematology, recently presented promising research results at the 23rd annual meeting of the American Society of Hematology (ASH23).
In his study, Dr. Fiskus presents tasquinimod, a minute compound recognized for its ability to inhibit tumor expansion.
The efficacy of this compound was explored in preclinical models of advanced MPNs, using mice implanted with human cells. The results were promising and suggest that tasquinimod could represent a feasible treatment option for some cases of MPN.
The research is in its early stages but this could represent a substantial advance in the search for effective therapies for these diseases. Further research is needed to evaluate the safety, tolerability and efficacy of the drug in a broader population. In addition, further research is needed to determine the optimal methods for integrating tasquinimod into the existing treatment landscape. This could involve employing the drug as a stand-alone therapy or in conjunction with other existing drugs.
Overall, the findings of Dr. Fiskus' study at ASH23 could bring hope to patients facing advanced MPN. While much remains to be done, the potential of tasquinimod offers a new avenue of exploration in the effort to eradicate cancer.
Source: Medriva
References
Medriva. (s.f.). The Potential of Tasquinimod in Treating Advanced Myeloproliferative Neoplasms: A Glimpse into the Future. https://medriva.com/cancer/the-potential-of-tasquinimod-in-treating-advanced-myeloproliferative-neoplasms-a-glimpse-into-the-future/
MD Anderson. (2023). MD Anderson Research Highlights: ASH 2023 Special Edition. https://www.mdanderson.org/newsroom/md-anderson-research-highlights–ash-2023-special-edition.h00-159624168.html
American Society of Hematology (ASH). (2023). 741 Preclinical Studies Demonstrating Efficacy of Tasquinimod in Models of Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase. https://ash.confex.com/ash/2023/webprogram/Paper185031.html